Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Neoplasm Metastasis 3Philadelphia Chromosome 2Ovarian Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myeloid, Chronic-Phase 2Leukemia 2Sarcoma 1Recurrence 1Peritoneal Neoplasms 1Neoplasm, Residual 1Leukemia, Myeloid 1Hematologic Diseases 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Blast Crisis 1Appendiceal Neoplasms 1

Interventions

relacorilant 1nilotinib 1Therapeutic Touch 1Standard of Care 1Radiotherapy 1Practice Guidelines as Topic 1Paclitaxel 1Methods 1Laparoscopy 1Fulvestrant 1Electrocardiography 1Educational Status 1Early Intervention, Educational 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × nilotinib × 90 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡